The authors reported a clear tau-dominant pattern when comparing plasma biomarkers across clinical groups in a single-centre cohort. The cross-sectional sample included 436 participants assessed at the Healthy Brain Ageing brain health and memory clinic. Investigators assayed 221 plasma analytes and found that phosphorylated tau species (pTau181/T205/T212/217/231) accounted for the majority of group differences. This concentration of signal within tau-related analytes framed subsequent analyses focused on tau-derived markers.
The cohort composition was heterogenous by clinical stage. The study team observed 186 participants with subjective cognitive decline (SCD), 228 with mild cognitive impairment (MCI), and 22 with AD dementia. Mean (SD) age reported was 70.2 (8.0) years and 67.2% of participants were female. The authors emphasised that these demographic and clinical distributions underpinned the biomarker comparisons presented.
Among the biomarker panel, eMTBR-tau showed the largest adjusted differences across clinical stages. Data indicated a 1.69-fold higher level in MCI than in SCD. The contrast was larger for AD dementia: 6.55-fold higher than SCD and 3.88-fold higher than MCI. The study team reported that all three stage-wise comparisons reached FDR-adjusted statistical thresholds (P < .001 as reported), making eMTBR-tau the most stage-discriminating analyte in this dataset.
These fold-changes were derived from the NULISAseq™ Neuro 220 Panel measurements performed on fasting plasma collected on assessment mornings. The authors did not report additional assay reproducibility metrics, nor did they provide absolute concentration units for eMTBR-tau in the abstract; those details are not included in the source text.
Investigators compared eMTBR-tau levels by plasma pTau217 status and by MCI subtype. The study team observed higher eMTBR-tau in pTau217-positive than in pTau217-negative participants. They also reported that multidomain amnestic MCI showed higher eMTBR-tau than SCD. The authors did not provide detailed subgroup counts for every comparison in the abstract; the source did not report those exact denominators here.
These subgroup observations support a relationship between eMTBR-tau and other tau biomarkers, although the source material stops short of mechanistic claims and does not report causal inference. Authors framed these results as supportive evidence for eMTBR-tau as a marker aligned with established phosphorylated tau signals.
A subset of the cohort had longitudinal follow-up approximately two years after baseline assessment. The cross-sectional dataset numbered 436, whereas 166 participants returned for follow-up around the two-year mark, per the source. The authors conducted exploratory analyses of clinical progression using preceding biomarker values.
In an MCI-to-AD conversion analysis, the study team described 40 individuals with MCI who had prior biomarker measures; six of those converted to AD dementia over roughly two years. Using cross-validated discrimination metrics, preceding eMTBR-tau produced an AUC of 0.936 for MCI-to-AD conversion. For comparison, BD-pTau217 yielded an AUC of 0.882 in the same exploratory analysis. The authors characterised this result as higher discrimination by eMTBR-tau, and they presented it as an encouraging signal for further evaluation.
Readers should note that the MCI-to-AD conversion analysis was explicitly labelled exploratory in the source. The reported conversion sample (6 of 40) is small, and the authors did not present fuller model-fitting or calibration statistics in the abstract; the source did not provide those methodological details in this summary.
The study was observational with longitudinal follow-up in a subset. Participants were assessed at the Healthy Brain Ageing program, University of Sydney, between October 2018 and April 2026, according to the authors. Fasting blood draws occurred on the morning of clinical assessment. Plasma analytes were quantified using the NULISAseq™ Neuro 220 panel. Plasma pTau217 status was measured using the SIMOA ALZpath platform, per the methods reported in the abstract. APOE ϵ4 carrier status was recorded and included as a variable of interest.
The authors stated that relative biomarker abundance comparisons were performed across clinical and biomarker-defined groups, and that preceding BD-pTau217 and eMTBR-tau levels were modelled individually and jointly to assess progression outcomes (SCD-to-MCI and MCI-to-AD) over approximately two years. The abstract did not list covariate adjustments or the full statistical modelling approach; those specifics were not reported in the source abstract.
This report is a preprint and has not been peer reviewed; the authors themselves noted that the work should not yet guide clinical practice. The exploratory longitudinal conversion analysis included a small number of converters (6 of 40 MCI in the analysed subset), which limits the precision and generalisability of reported discrimination metrics. The abstract does not provide full assay performance characteristics, nor does it report absolute concentrations or detailed subgroup denominators for every comparison; those elements are not present in the source text.
Investigators declared University of Sydney Human Research Ethics Committee approvals and reported that all participants provided written consent. The authors declared no competing interests and indicated that de-identified data are available on reasonable request subject to ethical approvals. Specific unanswered questions documented in the source include the need for further evaluation of eMTBR-tau as a progression marker and validation of the exploratory discrimination findings in larger, independent cohorts.
The article ends on recommendations for further evaluation rather than clinical application, and it remains subject to peer review and external validation before translation into practice.